Login to Your Account



Financings NEWS

Cedilla Therapeutics Inc., a startup harnessing protein stability mechanisms to broaden the reach of small-molecule drugs in cancer and other diseases, is debuting with $56.2 million in series A funding from Third Rock Ventures. The Cambridge, Mass.-based company, created last summer by academics at Harvard and University of California San Francisco and led by former Editas Medicine Inc. chief operating officer Alexandra Glucksmann, is seeking new points of intervention for diseases caused by protein dysregulation.

'We've demonstrated great momentum'

Revolution Medicines Inc. (Revmed) strengthened its balance sheet with a $56 million series B while bolstering its C-suite with a trio of executives. The financing will enable the company to advance its lead SHP2 program through IND and into what Mark Goldsmith, president and CEO, called an "exciting" clinical trial program.

LONDON – Bergenbio A/S raised NOK187.5 million (US$24 million) in a private placement of new shares, lengthening the cash runway as it awaits data from six ongoing phase II cancer trials and enabling the company to extend the applications of its Axl kinase inhibitor bemcentinib (BGB-324) to the treatment of fibrotic disorders.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: